Origin Asset Management LLP Biogen Inc. Transaction History

Origin Asset Management LLP

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Feb 12, 2021	SELL	$236.26 - $355.63 $1.46 Million - $2.2 Million	-6,182 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$264.77 - $305.71 $1.67 Million - $1.93 Million	-6,318 Reduced 50.54%	6,182 $1.75 Million
Q2 2020 Aug 13, 2020	SELL	$258.66 - $342.55 $310,392 - $411,060	-1,200 Reduced 8.76%	12,500 $3.34 Million
Q1 2020 May 05, 2020	SELL	$268.85 - $341.04 $5.24 Million - $6.65 Million	-19,500 Reduced 58.73%	13,700 $4.33 Million
Q3 2019 Oct 29, 2019	SELL	$217.44 - $243.88 $1.28 Million - $1.44 Million	-5,900 Reduced 15.09%	33,200 $7.73 Million

Q2 2019 Aug 09, 2019	SELL	$219.29 - $241.72 $4.32 Million - $4.76 Million	-19,700 Reduced 33.5%	39,100 $9.14 Million
Q1 2019 May 14, 2019	BUY	$216.71 - $338.96 $2.56 Million - $4 Million	11,800 Added 25.11%	58,800 $13.9 Million
Q4 2018 Feb 12, 2019	SELL	$278.5 - $352.75 $4.43 Million - $5.61 Million	-15,900 Reduced 25.28%	47,000 $14.1 Million
Q3 2018 Nov 13, 2018	BUY	$293.51 - $383.83 $7.48 Million - $9.79 Million	25,500 Added 68.18%	62,900 $22.2 Million
Q2 2018 Aug 14, 2018	SELL	$257.52 - $306.91 $12.3 Million - $14.7 Million	-47,900 Reduced 56.15%	37,400 $10.9 Million
Q1 2018 May 11, 2018	SELL	$260.13 - $367.91 $1.87 Million - $2.65 Million	-7,200 Reduced 7.78%	85,300 $23.4 Million
Q4 2017 Feb 13, 2018	SELL	$307.64 - $344.58 $1.17 Million - $1.31 Million	-3,800 Reduced 3.95%	92,500 $29.5 Million
Q3 2017 Nov 14, 2017	BUY	$281.15 - $329.69 $27.1 Million - $31.7 Million	96,300	96,300 $30.2 Million

1,047

126M

1.37M

1.35M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $32.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Origin Asset Management LLP, based on Form 13F filings with the SEC.

Stay updated on Origin Asset Management LLP with notifications on news.